# TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer

> **NCT05188313** · PHASE3 · RECRUITING · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 376 (estimated)

## Conditions studied

- Esophageal Cancer
- Esophageal Adenocarcinoma

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT05188313
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-09
- **Primary completion:** 2027-07
- **Final completion:** 2037-02
- **Target enrollment:** 376 (ESTIMATED)
- **Last updated:** 2022-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05188313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05188313, "TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05188313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*